Neutrophil chemotaxis in psoriasis.
Neutrophil chemotaxis was assessed in 69 psoriatic patients and 37 healthy human subjects. It was found to be significantly enhanced in 52 untreated patients. In 20 patients treated with an orally-administered phosphodiesterase inhibitor, Diphylline, neutrophil chemotaxis was normal. The enhanced chemotactic response of neutrophils from untreated patients with minimal skin lesions was at least equal to the response of those from patients with extensive skin lesions. Preincubation of normal human leukocytes with plasma derived from patients with widespread lesions markedly reduced their chemotactic activity. Plasma derived from patients with extensive skin lesions exhibited marked chemoattracting properties in comparison with plasma from healthy subjects. It is postulated that the basic intrinsic abnormality of neutrophil function in psoriasis could be caused by a decreased cyclic AMP/cyclic GMP ratio, similar to the decreased cyclic AMP/cyclic GMP ratio found in the lesional epidermis of this disease. Plasma factors which influence chemotaxis in psoriasis are related to the extent of the eruption and their effect is contrary to the effect of the basic intrinsic abnormality of psoriatic neutrophils.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002648:Child; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004817:Epidermis / Q000378:metabolism; D005029:Ethylenediamines / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology*; D012867:Skin / Q000378:metabolism; D013806:Theophylline / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D005029:Ethylenediamines; D010726:Phosphodiesterase Inhibitors; D013806:Theophylline; D000242:Cyclic AMP; D006152:Cyclic GMP; D006918:Hydroxyurea; D008727:Methotrexate